Supporting Information

Synthesis of Benzimidazole Fused Poly-heterocycles *via* Oxidant Free Cu-Catalyzed Dehydrogenative C-N Coupling and Photophysical Studies

Sakshi Singh and Shantanu Pal*

School of Basic Sciences (Chemistry), Indian Institute of Technology Bhubaneswar,

Argul, Khordha-752050, Odisha, India

Email: spal@iitbbs.ac.in, ss122@iitbbs.ac.in

Sl.no.	Contents	Page no.
1.	General Information	S 1
2.	Experimental Procedure	S2
3.	Experimental Procedure of Control Experiments	S15
4.	Gram Scale and Synthetic Versatility	S20
5.	References	S26
6.	Copy of ¹ H NMR & ¹³ C NMR Spectra	S27
7.	Photophysical studies	S68

1. General Information

The use of all chemicals was done without additional purification and they were all purchased from commercial providers. Silica gel with a mesh size of 100–200 was used for column chromatography purifications. Air and Moisture sensitive reaction were carried out in oven-dried glassware sealed with rubber septum under the positive pressure of argon/nitrogen gas. Reactions were stirred using magnetic bar over magnetic stirrer. Solvents were dried as per standard procedure. Analytical thin-layer chromatography (TLC) was done using Merck 60 F_{254} precoated silica gel plates (0.2 mm thickness). Plates were viewed using UV light (254 nm) on a Spectroline Model ENF-24061/F 254 nm after elution. NMR Spectra were measured on Bruker 400 NMR spectrometer (¹H at 400 MHz, ¹³C at 101 MHz). Data for ¹H spectra are as reported as follows: Chemical shift (ppm, reference to (CH₃)₄Si; s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublet, dt = double of triplet, ddd = doublet of doublet of doublet, m = multiplet), coupling constant (Hz), and Integration data for ¹³C-NMR are reported in terms of chemical shift (ppm) relative to residual solvent peak (CDCl₃: 77.0 ppm, DMSO-d₆: 39.9). High-resolution mass spectral analysis (HRMS) was performed on a Bruker Daltonics MicroTOF-Q-II mass spectrometer and Thermoscintific Exactive Plus ORBITRAP mass spectrometer using MeOH as a solvent with an electrospray ionization (ESI) positive method.

2. Experimental Procedure

2.1 General procedure for the synthesis of compounds (8-11):



An oven dried schlenk tube was filled with compound (4-7) (0.5 mmol), and Cu(OAc)₂ (20 mol%) in dry DMF solvent. The schlenk tube was flush with argon gas and maintain the inert atmosphere. The reaction mixture was stirred at 70 °C for 12 hours until the substrate was completely consumed (reaction monitor by TLC). After full conversion of starting material, the reaction mixture was brought to room temperature. Then solvent of reaction mixture was evaporated and extracted with ethyl acetate. The organic layer was washed with water and brine solution. The combined organic phase was dried over Na₂SO₄, filtered, and concentrated under reduced pressure then the crude product was purified by column chromatography over silica gel using a mixture of hexane/ ethyl acetate (4:1) as the eluent to afford cyclized product (8-11).

2.1.1 Characterization data for products (8-11)



Benzo[4,5]imidazo[1,2-a]pyrazolo[1,5-c]quinazoline (8a)

The compound **8a** was synthesized by the procedure as described general procedure above and obtained as a white solid: yield 85%; mp: 192 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.18 (d, *J* = 8.4 Hz, 1H), 8.06 (d, *J* = 1.8 Hz, 1H), 8.01 (d,

J = 8.1 Hz, 1H), 7.89 (d, J = 7.9 Hz, 2H), 7.59 – 7.52 (m, 1H), 7.40 (dd, J = 11.1, 4.1 Hz, 1H), 7.38 – 7.31 (m, 2H), 6.90 (d, J = 1.9 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 144.46, 142.53, 141.94, 137.20, 132.03, 130.90, 130.30, 125.35, 125.25, 124.48, 123.21, 120.71, 115.29, 115.19, 112.92, 101.16, 77.37, 77.05, 76.73. HRMS (ESI-ORBITRAP) Calculated for C₁₆H₁₁N₄ [M + H]⁺ 259.2840, found 259.0974.



10,11-Dimethylbenzo[4,5]imidazo[1,2-a]pyrazolo[1,5-c]quinazoline (8b)

The compound **8b** was synthesized by the procedure as described above and obtained as a white solid: yield 82 %; mp: $> 280 \text{ °C}^{-1}\text{H}$ NMR (400 MHz, CDCl₃)

δ 8.27 (d, J = 8.4 Hz, 1H), 8.09 (d, J = 1.6 Hz, 1H), 7.99 (d, J = 7.8 Hz, 1H), 7.82 (s, 1H), 7.65 (dd, J = 15.1, 6.9 Hz, 2H), 7.43 (t, J = 7.6 Hz, 1H), 6.96 (d, J = 1.5 Hz, 1H), 2.44 (s, 3H), 2.38 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 144.12, 141.35, 140.81, 137.05, 133.35, 132.17, 132.09, 130.15, 129.21, 125.19, 124.88, 120.72, 115.22, 115.02, 113.25, 100.88, 77.37, 77.05, 76.73, 20.88, 20.30. HRMS (ESI-ORBITRAP) Calculated for C₁₈H₁₅N₄ [M + H]⁺ 287.3380, found 287.1297.



11(10)-Methoxybenzo[4,5]imidazo[1,2-a]pyrazolo[1,5-c]quinazoline (8c, d)

The compounds (**8c**, **d**) were synthesized by the procedure as described above and obtained as an inseparable mixture of white solid: yield 80 %;

mp: 177 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.69 – 8.60 (m, 2H), 8.06 (d, *J* = 8.4 Hz, 1H), 7.95 – 7.88 (m, 1H), 7.66 (dd, *J* = 10.0, 5.0 Hz, 2H), 7.50 (dd, *J* = 5.4, 3.7 Hz, 2H), 7.43 (dd, *J* = 9.6, 5.5 Hz, 2H), 6.94 (dd, *J* = 8.8, 2.1 Hz, 1H), 3.87 (d, *J* = 8.7 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 157.03, 156.33, 144.37, 143.70, 140.95, 136.58, 134.02, 133.83, 131.93, 131.85, 130.45, 130.26, 126.55, 126.50, 125.29, 125.21, 125.17, 125.11, 124.29, 124.24, 124.17, 120.06, 119.56, 114.87, 114.63, 114.54, 114.46, 112.96, 111.87, 111.18, 102.68, 98.57, 77.35, 77.03, 76.71, 56.05, 55.62. HRMS (ASAP/Q-TOF) Calculated for C₁₇H₁₃N₄O [M + H]⁺ 289.3100, found 289.1086.

Benzo[4,5]imidazo[1,2-a]benzo[4,5]imidazo[1,2-c]quinazoline (9a)



The compound **9a** was synthesized by the procedure as described above and obtained as a white solid: yield 80 %; mp: 230 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.74 – 8.69 (m, 1H), 8.66 (dd, *J* = 7.8, 1.0 Hz, 1H), 8.22 (d, *J* = 8.4 Hz, 1H),

8.00 (d, J = 7.9 Hz, 1H), 7.96 – 7.90 (m, 1H), 7.86 – 7.80 (m, 1H), 7.74 – 7.67 (m, 1H), 7.55 – 7.49 (m, 2H), 7.47 (t, J = 7.6 Hz, 1H), 7.38 (dd, J = 11.3, 3.9 Hz, 1H), 7.36 – 7.31 (m, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 144.53, 143.80, 142.52, 141.65, 134.08, 131.99, 130.34, 130.07, 126.59, 125.34, 125.33, 124.39, 124.25, 123.08, 120.04, 119.63, 114.99, 114.92, 114.50, 112.65, 77.35, 77.03, 76.72. HRMS (ESI-ORBITRAP) Calculated for C₂₀H₁₃N₄ [M + H]⁺ 309.1062, found 309.1139.



12,13-Dimethylbenzo[4,5]imidazo[1,2-a]benzo[4,5]imidazo[1,2-c]quin - azoline (9b)

The compound **9b** was synthesized by the procedure as described above and obtained as a white solid: yield 78 %; mp: 145 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.79 (d, *J* = 8.0 Hz, 2H), 8.38 (d, *J* = 8.4 Hz, 1H), 7.99 (s, 1H),

7.92 (s, 1H), 7.83 (s, 1H), 7.70 (s, 1H), 7.57 (m, 3H), 2.50 (s, 3H), 2.45 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 142.58, 141.03, 134.41, 133.28, 132.16, 132.08, 130.45, 128.60, 126.68, 125.31, 125.17, 124.34, 120.38, 119.62, 115.47, 115.07, 114.57, 114.51, 113.61, 113.25, 77.34, 77.02, 76.70, 20.87, 20.29. HRMS (ESI-ORBITRAP) Calculated for C₂₂H₁₇N₄ [M + H]⁺ 337.1375, found 337.1444.



Dimethyl benzo[4,5]imidazo[1,2-a]benzo[4,5]imidazo[1,2-c]quin - azoline-12,13-dicarboxylate (9c)

The compound **9c** was synthesized by the procedure as described above and obtained as a white solid: yield 79 %; mp: 244 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.76 (dd, *J* = 7.9, 1.2 Hz, 1H), 8.72 (dd, *J* = 6.4, 2.8 Hz,

1H), 8.57 (s, 1H), 8.37 (d, J = 8.4 Hz, 1H), 8.22 (s, 1H), 7.99 – 7.93 (m, 1H), 7.90 – 7.83 (m, 1H), 7.62 (t, J = 7.6 Hz, 1H), 7.58 – 7.51 (m, 2H), 4.02 (s, 3H), 4.01 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 168.21, 167.96, 144.54, 144.42, 144.19, 143.93, 133.51, 132.56, 131.19, 130.29, 129.15, 126.99, 126.49, 126.39, 125.89, 124.96, 120.82, 119.96, 115.34, 115.01, 114.93, 114.24, 77.34, 77.02, 76.70, 53.02, 52.91. HRMS (ESI-ORBITRAP) Calculated for C₂₄H₁₇N₄O₄ [M + H]⁺ 425.1172, found 425.1250.



13(12)-Methoxybenzo[4,5]imidazo[1,2-a]benzo[4,5]imidazo[1, 2c]quinazoline (9d, e)

The compound (**9d**, **e**) was synthesized by the procedure as described above and obtained as an inseparable mixture of a white solid: yield 75 %; mp: 172 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.68 – 8.59 (m,

2H), 8.06 (d, J = 8.4 Hz, 1H), 7.96 – 7.88 (m, 1H), 7.65 (d, J = 8.7 Hz, 2H), 7.50 (dd, J = 5.4, 3.7 Hz, 2H), 7.47 – 7.39 (m, 2H), 6.94 (dd, J = 8.8, 2.1 Hz, 1H), 3.88 (s, 2H), 3.86 (s, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 157.03, 156.33, 144.37, 143.70, 140.95, 136.58, 134.02, 133.83, 131.93, 131.85, 130.45, 130.26, 126.55, 126.50, 125.29, 125.21, 125.17, 125.11, 124.29, 124.24, 124.17, 120.06, 119.56, 114.87, 114.63, 114.54, 114.46, 112.96, 111.87, 111.18, 102.68, 98.57, 77.35, 77.03, 76.71, 56.05. HRMS (ESI-ORBITRAP) Calculated for C₂₁H₁₅N₄O [M + H]⁺ 339.1168, found 339.1239.



Ethyl 2-methylbenzo[4,5]imidazo[1,2-a]pyrazolo[1,5-c]quinazoline-3-carboxylate (10)

The compound **10** was synthesized by the procedure as described above and obtained as a white solid: yield 71 %; mp: 220 °C. ¹H NMR (400

MHz, CDCl₃) δ 9.58 (dd, J = 8.3, 1.4 Hz, 1H), 8.45 (d, J = 7.8 Hz, 1H), 8.22 (dd, J = 7.4, 1.2 Hz, 1H), 8.03 – 7.96 (m, 1H), 7.81 (ddd, J = 8.6, 7.3, 1.5 Hz, 1H), 7.61 – 7.44 (m, 3H), 4.50 (q, J = 7.1 Hz, 2H), 2.75 (s, 3H), 1.50 (t, J = 7.1 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 164.19, 156.68, 142.78, 141.09, 138.57, 132.97, 131.60, 130.79, 129.17, 125.22, 124.85, 123.36, 120.85, 114.90, 114.65, 113.26, 110.01, 77.34, 77.02, 76.71, 61.13, 15.71, 14.34. HRMS (ASAP/Q-TOF) Calculated for C₂₀H₁₆N₄O₂Na [M + Na]⁺ 367.3638, found 367.1172.



Bis-benzimidazole (11)

The compound **11** was synthesized by the procedure as described above and obtained as a white solid: yield 58 %; mp: > 250 °C; ¹H NMR (400

MHz, DMSO) δ 7.62 (dd, J = 6.2, 2.9 Hz, 1H), 7.54 (dd, J = 5.8, 3.3 Hz, 1H), 7.50 (d, J = 7.8 Hz, 1H), 7.44 (d, J = 7.8 Hz, 1H), 7.19 (t, J = 3.6 Hz, 1H), 7.17 (d, J = 3.2 Hz, 1H), 7.13 (d, J = 4.8 Hz, 1H), 7.10 (d, J = 7.1 Hz, 1H), 5.68 (s, 2H). ¹³C NMR (101 MHz, DMSO) δ 145.55, 143.44, 136.58, 123.21, 122.78, 122.78, 122.42, 122.42, 121.89, 121.89, 119.15, 118.75, 111.92, 110.92, 45.25, 40.57, 40.36, 40.15, 39.94, 39.74, 39.53, 39.32. HRMS (ESI-ORBITRAP) Calculated for C₂₀H₁₇N₄O₂ [M + H]⁺ 247.0905, found 247.0984.

2.2 General procedure for the synthesis of compounds (10aa-ac):

An oven dried schlenk tube was filled with compound **3a** (0.5 mmol), ethylenediamine (0.5 mmol) and K_2CO_3 in dry DMF solvent. The schlenk tube was flush with argon gas and maintain the inert atmosphere. The reaction mixture was stirred at 70 °C for 5 hours. After full conversion of starting material, Cu(OAc)₂ (20 mol%) was added in reaction mixture and further stirred at 70 °C for 12 hours until the substrate was completely consumed (reaction monitor by TLC). Then DMF solvent of evaporated DMF and extracted with ethyl acetate. The organic layer was washed with water and brine solution. The combined organic phase was dried over Na₂SO₄, filtered, and concentrated under reduced pressure then the crude product was purified by column chromatography over silica gel using a mixture of hexane/ethyl acetate (1:99) as the eluent to afford solid product **10aa-ac**.

2.2.1 Characterization data for products (10aa-ac)

1,2-dihydrobenzo[4,5]imidazo[1,2-a]imidazo[1,2-c]quinazoline (10aa)



The compound **10aa** was synthesized by the procedure as described above and obtained as a white solid: yield 85 %; mp: 222 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.17 (d, *J* = 7.6 Hz, 1H), 7.94 (d, *J* = 8.2 Hz, 1H), 7.76 (d, *J* = 7.8 Hz, 1H), 7.61 (dd,

J = 15.4, 7.7 Hz, 2H), 7.33 - 7.26 (m, 2H), 7.20 (t, J = 7.6 Hz, 1H), 4.21 (s, 4H). ¹³C NMR (101 MHz, CDCl₃) δ 152.44, 145.66, 143.11, 136.27, 133.33, 130.88, 127.82, 124.81, 123.64, 121.59, 118.46, 114.62, 114.32, 111.56, 77.38, 77.06, 76.74, 54.36, 46.16. HRMS (ESI-ORBITRAP) Calculated for C₁₆H₁₃N₄ [M + H]⁺ 261.1062, found 261.1130.



10,11-dimethyl-1,2-dihydrobenzo[4,5]imidazo[1,2-a]imidazo[1,2-c]quinazoline (10ab)

The compound **10ab** was synthesized by the procedure as described above and obtained as a white solid: yield 81 %; mp: 239 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.19 (dd, *J* = 7.8, 1.3 Hz, 1H), 7.96 (d, *J* = 8.4 Hz, 1H), 7.71 – 7.63 (m, 1H),

7.53 (s, 1H), 7.35 (s, 1H), 7.31 (t, J = 7.5 Hz, 1H), 4.23 (s, 4H), 2.39 (s, 3H), 2.34 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 152.69, 145.18, 141.36, 136.44, 133.26, 132.16, 130.12, 129.20, 127.77, 124.48, 118.95, 114.58, 114.18, 112.31, 77.36, 77.04, 76.73, 54.27, 46.20, 20.61, 20.18. HRMS (ESI-ORBITRAP) Calculated for C₁₈H₁₇N₄ [M + H]⁺ 289.1375, found 289.1453.



Dimethyl 1,2-dihydrobenzo[4,5]imidazo[1,2-a]imidazo[1,2-c]quinazoline-10,11-dicarboxylate (10ac)

The compound **10ac** was synthesized by the procedure as described above and obtained as a white solid: yield 79 %; mp: 248 °C; ¹H NMR

(400 MHz, CDCl₃) δ 8.26 (d, *J* = 4.8 Hz, 2H), 8.07 (d, *J* = 8.4 Hz, 1H), 7.86 (s, 1H), 7.76 (t, *J* = 7.8 Hz, 1H), 7.42 (t, *J* = 7.5 Hz, 1H), 4.29 (s, 4H), 3.96 (d, *J* = 6.1 Hz, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 168.57, 167.98, 151.83, 148.02, 145.48, 135.55, 133.78, 131.91, 128.90, 128.13, 125.89, 124.55, 118.71, 114.99, 114.62, 112.78, 77.35, 77.03, 76.71, 54.57, 52.81, 52.78, 46.18. HRMS (ESI-ORBITRAP) Calculated for C₂₀H₁₇N₄O₄ [M + H]⁺ 377.1172, found 377.1250.

2.3 General procedure for synthesizing compound type (5)



2.3.1 General procedure for synthesizing compound type $(3a)^1$:



An oven dried 25 ml round-bottom flask was taken benzimidazole (1.0 equiv, 6.8 mmol), 2-florobenzaldehyde (2.0 equiv, 13.6 mmol), and K_2CO_3 (2.0 equiv, 13.6 mmol) in DMF (5.0 ml) were added, and the reaction was stirred at 90 °C for 16 hours. Upon the completion of the reaction (confirm by TLC), the solvent was removed under reduced pressure, and the residue was dissolved in ethyl acetate. The organic layer was washed with water, dried over anhydrous Na₂SO₄, and removed under the reduced pressure. The crude was purified with silica gel column chromatography to afford the target compound of type **3a**.

Characterization data for products (3aa-ag) 2.3.1.1



2-(1H-Benzo[d]imidazol-1-yl) benzaldehyde (3aa)

The compound 3aa was synthesized by the procedure as described above and obtained as a yellow sticky compound: yield 75 %; ¹H NMR (400 MHz, CDCl₃) δ 9.69 (s, 1H), 8.12 (d, J = 7.8 Hz, 1H), 8.08 (d, J = 5.6 Hz, 1H), 7.87 (dd, J = 8.2, 7.4 Hz, 1H), 7.81 (dd, J = 8.2, 7.4 Hz, 1 J = 14.7, 7.1 Hz, 1H), 7.67 (dd, J = 11.2, 4.0 Hz, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.31 (tt, J = 13.4, 6.7 Hz, 2H), 7.21 (d, J = 7.9 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 188.42, 143.35, 143.29, 137.82, 135.75, 135.53, 131.60, 129.68, 129.63, 127.96, 124.45, 123.33, 120.71, 110.00, 77.47, 77.15, 76.84. HRMS (ESI-ORBITRAP) Calculated for $C_{14}H_{11}N_2O [M + H]^+ 223.0793$, found 223.0862.

2-(5,6-Dimethyl-1H-benzo[d]imidazol-1-yl)benzaldehyde (3ab)



The compound **3ab** was synthesized by the procedure as described above and obtained as a white solid: 64% yield; ¹H NMR (400 MHz, CDCl3) δ 9.69 (s, 1H), 8.11 (dd, J = 7.8, 1.5 Hz, 1H), 7.94 (s, 1H), 7.79 (td, J = 7.7, 1.6 Hz, 1H), 7.70–7.58

(m, 2H), 7.47 (dd, J = 7.9, 0.8 Hz, 1H), 6.98 (s, 1H), 2.37 (s, 3H), 2.30 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 188.5, 142.5, 141.9, 138.3, 135.4, 134.4, 133.8, 132.3, 131.6, 129.4, 129.3, 127.8, 120.6, 110.0, 77.47, 77.15, 76.83, 20.5, 20.2; HRMS (ESI-ORBITRAP) m/z [M + H]⁺ calculated for C₁₆H₁₅N₂O 251.1179, found 251.1181.



Dimethyl 1-(2-formylphenyl)-1H-benzo[d]imidazole-5,6-dicarboxylate (**3ac**)

The compound **3ac** was synthesized by the procedure as described above and obtained as a colourless sticky compound: yield 55 %; ¹H NMR (400 MHz, CDCl₃) δ 9.74 (s, 1H), 8.30 (s, 1H), 8.21 (s, 1H), 8.16 (dd, J = 7.7, 1.5 Hz,

1H), 7.87 (td, *J* = 7.7, 1.6 Hz, 1H), 7.77 (t, *J* = 7.5 Hz, 1H), 7.57 (s, 1H), 7.52 (dd, *J* = 7.8, 0.8 Hz, 1H), 3.95 (s, 3H), 3.88 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) & 187.88, 168.21, 168.02, 146.45, 144.49, 136.53, 136.05, 135.62, 131.70, 131.16, 130.50, 128.65, 128.34, 127.43, 122.41, 111.59, 77.47, 77.15, 76.83, 52.85, 52.82. HRMS (ESI-ORBITRAP) Calculated for C₁₈H₁₄N₂O₅ [M + H]⁺ 339.0903, found 339.0970.

2-(5(6)-methoxy-1H-benzo[d]imidazol-1-yl) benzaldehyde (3ad, ae)



The compound (3ad, ae) was synthesized by the procedure as described above and obtained as an inseparable mixture yellow sticky compound, 68% yield; ¹H NMR (400 MHz, CDCl3) δ 9.78–9.69 (s, 1H), 8.13 (ddd, J = 7.9,

6.6, 1.5 Hz, 1H), 7.99 (d, J = 21.6 Hz, 1H), 7.81 (qd, J = 7.6, 1.6 Hz, 1H), 7.76, 7.11 (d, 1H), 7.67 (q, J = 7.4 Hz, 1H), 7.50 (d, J = 7.9 Hz, 1H), 6.64 (d, 1H), 6.96 (td, J = 9.1, 2.4 Hz, 1H), 3.82 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 188.4, 188.8, 157.8, 156.8, 144.3, 143.5, 142.4, 138.0, 137.7, 136.4, 135.5, 135.4, 131.6, 131.5, 130.4, 129.6, 129.5, 127.8, 127.7, 121.2, 114.5, 112.7, 110.4, 102.6, 93.1, 77.43, 77.11, 76.79, 55.8; HRMS (ESI-ORBITRAP) m/z $[M + H]^+$ calculated for $C_{15}H_{13}N_2O_2$ 253.0972, found 253.0976.

H/O₂N O₂N/H

2-(5(6)-Nitro-1H-benzo[d]imidazol-1-yl) benzaldehyde (3af, ag)

The compound (**3af, ag**) was synthesized by the procedure as described above and obtained as an inseparable mixture of yellow solid, 63% yield; ¹H NMR (400 MHz, CDCl3) δ 9.77 (s, 1H), 8.77 (d, J = 2.1 Hz, 1H), 8.29–8.19 (m, 2H), 8.18-8.09 (m, 1H), 7.93-7.85 (m, 1H), 7.80 (td, J = 8.4, 0.6 Hz, 1H,), 7.57-7.52 (m, J = 7.8, 4.8, 0.9 Hz, 1H), 7.29–7.22 (m, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 188.0, 188.0, 147.7, 147.6, 146.5,

144.7, 144.3, 142.8, 139.3, 135.6, 135.3, 134.8, 132.0, 131.6, 131.5, 130.7, 130.6, 128.4, 128.3, 121.0, 119.9, 118.8, 117.4, 110.2, 107.1, 77.40, 77.09, 76.77; HRMS (ESI-ORBITRAP) m/z [M + H]⁺ calculated for C₁₄H₁₀N₃O₃ 268.0717, found 268.0719.

2.3.2 General procedure for synthesizing compound (5):



An oven dried 25 ml round-bottom flask was taken compound **3a** (1.0 equiv, 3.2 mmol), and benzene-1,2-diamine (1.0 equiv, 3.2 mmol) in DMSO (3.0 ml) were added, and the reaction was stirred at 80 °C for 8 hours. Upon the completion of the reaction (confirm by TLC), and the reaction mixture was dissolved in ethyl acetate. Then the organic layer was washed with water, dried over anhydrous Na₂SO₄, and removed under the reduced pressure. The crude was purified with silica gel column chromatography to afford the target compound of type **5**.

Characterization data for products (5a-g) 2.3.2.1



2-(2-(1H-benzo[d]imidazol-1-yl)phenyl)-1H-benzo[d]imidazole (5a)

The compound 5a was synthesized by the procedure as described above and obtained as a white solid: yield 78 %; mp: 198 °C; ¹H NMR (400 MHz, DMSO *d*₆) δ 12.56 (s, 1H), 8.25 (s, 1H), 8.07 – 7.99 (m, 1H), 7.79 – 7.71

(m, 2H), 7.67 (dd, J = 9.6, 4.9 Hz, 2H), 7.42 (d, J = 7.3 Hz, 1H), 7.37 (d, J = 7.2 Hz, 1H), 7.18 – 7.05 (m, 5H). ¹³C NMR (101 MHz, DMSO d_6) δ 149.23, 144.98, 143.92, 143.59, 134.90, 134.75, 134.49,

131.96, 131.53, 129.44, 128.66, 128.30, 123.42, 123.04, 122.36, 121.94, 120.01, 119.50, 111.86, 110.49, 40.62, 40.41, 40.20, 39.99, 39.78, 39.58, 39.37. HRMS (ESI-ORBITRAP) m/z $[M + H]^+$ calculated for C₂₀H₁₅N₄ 311.1218, found 311.1297.



1-(2-(1H-benzo[d]imidazol-2-yl)phenyl)-5,6-dimethyl-1H-benz - o[d]imidazole (5b)

The compound **5b** was synthesized by the procedure as described above and obtained as a white solid: yield 75 %; mp: 201 °C; ¹H NMR (400

MHz, DMSO d_6) δ 12.51 (s, 1H), 8.02 (s, 1H), 7.98 (dd, J = 7.4, 1.7 Hz, 1H), 7.77 – 7.68 (m, 2H), 7.63 (dd, J = 7.5, 1.3 Hz, 1H), 7.44 (d, J = 7.8 Hz, 1H), 7.40 (d, J = 7.9 Hz, 1H), 7.36 (d, J = 7.7 Hz, 1H), 7.13 (t, J = 7.6 Hz, 1H), 7.08 (t, J = 7.5 Hz, 1H), 6.92 (s, 1H), 2.23 (s, 3H), 2.15 (s, 3H). ¹³C NMR (101 MHz, DMSO d_6) δ 149.34, 143.97, 143.90, 142.06, 134.90, 134.78, 133.30, 132.10, 132.00, 131.53, 130.78, 129.23, 128.46, 128.33, 123.03, 121.94, 120.02, 119.47, 111.87, 110.66, 40.56, 40.35, 40.14, 39.93, 39.72, 39.51, 39.31, 20.38, 20.23. HRMS (ESI-ORBITRAP) m/z [M + H]⁺ calculated for C₂₂H₁₉N₄ 339.1531, found 339.1597.



Dimethyl 1-(2-(1H-benzo[d]imidazol-2-yl)phenyl)-1H-ben zo[d]imidazole-5,6-dicarboxylate (5c)

The compound **5c** was synthesized by the procedure as described above and obtained as a white solid: yield 75 %; mp: 165 °C; ¹H NMR (400 MHz, DMSO d_6) δ 12.72 (s, 1H), 8.52 (s, 1H), 8.09 (dd, J = 5.8, 2.9 Hz, 1H), 8.03 (s, 1H), 7.82 – 7.76 (m, 3H), 7.43 (s, 1H),

7.40 (d, J = 7.9 Hz, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.16 – 7.10 (m, 1H), 7.08 – 7.02 (m, 1H), 3.79 (s, 3H), 3.72 (s, 3H). ¹³C NMR (101 MHz, DMSO d_6) δ 168.20, 167.87, 148.96, 148.65, 144.65, 143.90, 136.18, 134.79, 133.37, 131.60, 131.48, 130.33, 129.24, 128.33, 126.92, 126.45, 123.27, 122.06, 120.98, 119.53, 111.94, 111.84, 52.97, 52.95, 40.61, 40.40, 40.19, 39.91, 39.77, 39.56, 39.35. HRMS (ASAP/Q-TOF) m/z [M + Na]⁺ calculated for C₂₄H₁₈N₄O₄Na 449.1226, found 449.1226.



1-(2-(1H-benzo[d]imidazol-2-yl)phenyl)-5(6)-methoxy-1H-benzo[d]imidazole (5d, e)

The compound (**5d**, **e**) was synthesized by the procedure as described above and obtained as an inseparable mixture of white solid: yield 69 %; mp: 197 °C; ¹H NMR (400 MHz, DMSO d_{δ}) δ

12.51 (s, 2H), 8.15 (d, J = 7.5 Hz, 2H), 8.00 (dd, J = 7.3, 1.8 Hz, 2H), 7.71 (dtdd, J = 19.8, 12.4, 7.2, 1.4 Hz, 6H), 7.51 (d, J = 8.8 Hz, 1H), 7.45 (d, J = 7.7 Hz, 2H), 7.36 (t, J = 7.6 Hz, 2H), 7.18 (d, J = 2.3 Hz, 1H), 7.09 (dd, J = 16.8, 8.3 Hz, 4H), 6.97 (d, J = 8.8 Hz, 1H), 6.71 (dd, J = 8.7, 2.2 Hz, 2H), 6.51

(d, J = 2.3 Hz, 1H), 3.73 (s, 2H), 3.54 (s, 1H). ¹³C NMR (101 MHz, DMSO d_6) δ 156.68, 155.97, 149.45, 149.29, 145.11, 144.46, 143.92, 143.86, 137.83, 135.11, 134.92, 134.66, 134.62, 132.14, 132.03, 131.64, 131.54, 129.27, 128.45, 128.35, 128.19, 128.08, 123.03, 121.94, 120.44, 119.51, 119.43, 112.97, 112.01, 111.88, 111.83, 110.83, 102.54, 93.55, 55.90, 55.69, 40.61, 40.45, 40.40, 40.21, 39.99, 39.78, 39.57. HRMS (ESI-ORBITRAP) m/z [M + H]⁺ calcd for C₂₁H₁₇N₄O 341.1324, found 341.1397.



1-(2-(1H-benzo[d]imidazol-2-yl)phenyl)-5(6)-nitro-1H-benzo-[d]imidazole (5f, g)

The compound (**5f**, **g**) was synthesized by the procedure as described above and obtained as an inseparable mixture of white solid: yield 63 %; mp: 169 °C; ¹H NMR (400 MHz, DMSO d_6) δ 12.76 (s, 1H), 8.59

(d, J = 3.3 Hz, 1H), 8.16 – 7.99 (m, 2H), 7.89 (dd, J = 5.2, 3.4 Hz, 1H), 7.85 – 7.72 (m, 3H), 7.35 (d, J = 35.1 Hz, 2H), 7.30 – 7.24 (m, 1H), 7.08 (d, J = 31.7 Hz, 2H). ¹³C NMR (101 MHz, DMSO d_6) δ 150.38, 149.22, 148.61, 148.11, 143.35, 142.92, 139.50, 133.31, 131.59, 131.40, 130.45, 129.31, 128.23, 123.28, 122.09, 119.13, 116.21, 111.88, 111.19, 107.19, 40.59, 40.38, 40.17, 39.96, 39.75, 39.55, 39.34. HRMS (ESI-ORBITRAP) m/z [M + H]⁺ calculated for C₂₀H₁₄N₅O₂ 356.1069, found 356.1140.

2.4 General procedure for synthesizing compound type (4)¹:



2.4.1 General procedure for synthesizing compound type (3b)¹:



An oven dried 25 ml round-bottom flask was taken benzimidazole (1.0 equiv, 6.8 mmol), 2floroacetophenone (2.0 equiv, 13.6 mmol), and K_2CO_3 (2.0 equiv, 13.6 mmol) in DMF (5.0 ml) were added, and the reaction was stirred at 90 °C for 16 hours. Upon the completion of the reaction (confirm by TLC), the solvent was removed under reduced pressure, and the residue was dissolved in ethyl acetate. The organic layer was washed with water, dried over anhydrous Na₂SO₄, and removed under the reduced pressure. The crude was purified with silica gel column chromatography to afford the target compounds of type **3b**.

2.4.1.1 Characterization data for products (3ba-bd)

1-(2-(1H-benzo[d]imidazol-1-yl)phenyl)ethan-1-one (3ba)



The compound **3ba** was synthesized by the procedure as described above and obtained as a colourless sticky liquid: yield 70%; ¹H NMR (400 MHz, CDCl₃) δ 8.00 (s, 1H), 7.88 (d, *J* = 7.6 Hz, 1H), 7.82 (d, *J* = 7.7 Hz, 1H), 7.69 (t, *J* = 7.6

Hz, 1H), 7.60 (t, J = 7.6 Hz, 1H), 7.45 (d, J = 7.8 Hz, 1H), 7.37 – 7.27 (m, 2H), 7.22 (d, J = 7.7 Hz, 1H), 1.92 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 199.68, 137.31, 133.67, 132.88, 130.03, 129.42, 127.97, 124.21, 123.12, 120.69, 110.06, 77.43, 77.11, 76.79, 28.80. HRMS (ESI-ORBITRAP) m/z [M + H]⁺ calculated for C₁₅H₁₃N₂O 237.0950, found 237.1019.

1-(2-(5,6-dimethyl-1H-benzo[d]imidazol-1-yl)phenyl)ethan-1-one (3bb)



The compound **3bb** was synthesized by the procedure as described above and obtained as a colourless sticky liquid: yield 62%; ¹H NMR (400 MHz, CDCl₃) δ 7.87 (s, 1H), 7.81 (dd, *J* = 7.7, 1.4 Hz, 1H), 7.70 (td, *J* = 7.7, 1.6 Hz, 1H), 7.64

(s, 1H), 7.60 (td, J = 7.6, 1.0 Hz, 1H), 7.46 (d, J = 7.8 Hz, 1H), 7.01 (s, 1H), 2.39 (s, 3H), 2.33 (s, 3H), 1.89 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 200.03, 142.08, 137.42, 134.07, 133.63, 133.36, 132.80, 132.20, 129.96, 129.18, 127.78, 127.79, 120.63, 110.09, 77.37, 77.05, 76.73, 28.80, 20.61, 20.32. HRMS (ESI-ORBITRAP) m/z [M + H]⁺ calculated for C₁₇H₁₇N₂O 265.1263, found 265.1333.

H₃CO N N O

1-(2-(5-methoxy-1H-benzo[d]imidazol-1-yl)phenyl)ethan-1-one (3bc)

The compound (**3bc**) was synthesized by the procedure as described above and obtained as colourless sticky liquid: yield 68%; ¹H NMR (400 MHz, CDCl₃) δ 7.90 (s, 1H), 7.86 – 7.80 (m, 1H), 7.75 (d, *J* = 8.9 Hz, 1H), 7.71 (dd, *J* = 8.3,

7.1 Hz, 1H), 7.62 (t, J = 7.3 Hz, 1H), 7.47 (d, J = 7.8 Hz, 1H), 6.98 (dd, J = 8.8, 2.2 Hz, 1H), 6.64 (d, J = 2.0 Hz, 1H), 3.78 (s, 3H), 1.93 (s, J = 10.2 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 199.86, 157.75, 137.46, 133.77, 132.87, 130.04, 129.37, 127.80, 121.25, 112.76, 93.16, 77.34, 77.02, 76.71, 55.84, 28.80. HRMS (ESI-ORBITRAP) m/z [M + H]⁺ calculated for C₁₆H₁₅N₂O₂ 267.1055, found 267.1123.

2.4.2 General procedure for synthesizing compound (4):



An oven dried 25 ml round-bottom flask was taken compound **3b** (1.0 equiv, 0.84 mmol), and DMF-DMA (1.5 equiv, 1.26 mmol) in DMF solvent were added, and the reaction was stirred to reflux overnight. Upon the completion of the reaction (confirm by TLC), the solvent was removed under reduced pressure, and the residue was dissolved in ethyl acetate. The organic layer was washed with water, dried over anhydrous Na_2SO_4 , and removed under the reduced pressure. The crude was again treated with hydrazine hydrate (2.0 equiv, 0.49 mmol) in ethanol under reflux condition for 4 hours. Upon the completion of the reaction (confirm by TLC), the solvent was removed under reduced pressure, and the residue was dissolved in ethyl acetate. The organic layer was washed with water, dried over anhydrous Na_2SO_4 , and removed under the reduced pressure. The crude was gel column chromatography to afford the target compound of type **4**.

2.4.2.1 Characterization data for products (4a-d)



1-(2-(1H-pyrazol-5-yl)phenyl)-1H-benzo[d]imidazole (4a)

The compound **4a** was synthesized by the procedure as described above and obtained as a white solid: yield 75%; mp: 188 - 190 °C; ¹H NMR (400 MHz, DMSO d_6) δ 12.88 (s, 1H), 8.22 (s, 1H), 8.04 (d, J = 7.6 Hz, 1H), 7.72 (d, J =

7.9 Hz, 1H), 7.63 (t, J = 7.1 Hz, 1H), 7.55 (t, J = 7.4 Hz, 1H), 7.50 (d, J = 10.2 Hz, 2H), 7.26 – 7.19 (m, 1H), 7.16 (t, J = 7.4 Hz, 1H), 7.01 (d, J = 7.9 Hz, 1H), 5.26 (s, 1H). ¹³C NMR (101 MHz, DMSO d_{δ}) δ 147.01, 144.58, 143.41, 135.15, 132.94, 132.23, 130.07, 130.04 129.93, 129.18, 129.12, 123.55, 122.37, 120.04, 110.77, 103.47, 40.61, 40.45, 40.40, 40.24, 40.20, 39.99, 39.78. HRMS (ESI-ORBITRAP) m/z [M + H]⁺ calculated for C₁₆H₁₃N₄ 261.1062, found 261.1130.

1-(2-(1H-pyrazol-3-yl)phenyl)-5,6-dimethyl-1H-benzo[d]imidazole (4b)



The compound **4b** was synthesized by the procedure as described above and obtained as a white solid: yield 73%; mp: 193 °C; ¹H NMR (400 MHz, DMSO d_6) δ 12.88 (s, 1H), 8.01 (s, 2H), 7.58 (d, J = 31.3 Hz, 4H), 7.48 (s,

2H), 6.81 (s, 1H), 2.29 (s, 3H), 2.20 (s, 3H). ¹³C NMR (101 MHz, DMSO d_6) δ 143.58, 143.10, 141.88, 134.56, 133.73, 133.14, 132.76, 132.37, 130.90, 130.87, 129.86, 129.23, 120.05, 113.04, 110.68,

103.45, 40.54, 40.33, 40.12, 39.91, 39.71, 39.50, 39.29, 20.40, 20.30. HRMS (ESI-ORBITRAP) m/z $[M + H]^+$ calculated for $C_{18}H_{17}N_4$ 289.1375, found 289.1453.



1-(2-(1H-pyrazol-3-yl)phenyl)-5(6)-methoxy-1H-benzo[d]imidazole (4c, d)

(4c, d) was synthesized by the procedure as described above and obtained as an inseparable mixture of white solid: yield 65%; mp: 196 °C; ¹H NMR (400 MHz, DMSO d_6) δ 12.87 (s, 1H), 8.10 – 7.97 (m, 2H), 7.58 (dd, J = 17.8, 9.0 Hz, 3H), 7.50 (s, 2H), 6.82 (d, J = 8.7 Hz, 1H), 6.43 (s, 1H), 5.29 (s, 1H), 3.78 (s, 1H), 3.61 (s, 3H). ³C NMR (101 MHz, DMSO d_6) δ 156.89, 147.14, 143.56, 137.73, 135.66, 133.07, 132.10, 130.17, 129.94, 129.83, 129.21, 129.01, 120.56, 111.99, 103.57, 93.70, 55.85, 40.61, 40.40, 40.19, 39.98, 39.78, 39.57, 39.36. HRMS (ESI-ORBITRAP) m/z [M + H]⁺ calculated for C₁₇H₁₅N₄O 291.1168, found 291.1248.

2.5 Synthetic procedure for compound (6):



An oven dried 25 ml round-bottom flask was taken compound **3a** (1.0 equiv, 1.12 mmol), EAA (1.1 equiv, 1.23 mmol), and piperidine (0.05 equiv, 0.05 mmol) in CH₃CN were added and stirred the reaction mixture at room temperature overnight. Upon the completion of the reaction (confirm by TLC), the solvent was removed under reduced pressure, and the residue was dissolved in ethyl acetate. The organic layer was washed with water, dried over anhydrous Na_2SO_4 , and removed under the reduced pressure. The crude was purified with silica gel column chromatography to afford the target compound **6a**.

The compound **6a** was again treated with hydrazine hydrate (2.0 equiv, 1.79 mmol) in ethanol solvent under reflux condition for 6 hours. Upon the completion of the compound **6a** (confirm by TLC), the solvent was removed under reduced pressure, and the residue was dissolved in ethyl acetate. The organic layer was washed with water, dried over anhydrous Na_2SO_4 , and removed under the reduced pressure. The crude was purified with silica gel column chromatography to afford the target compound **6**.



Ethyl 5-(2-(1H-benzo[d]imidazol-1-yl)phenyl)-3-methyl-1H-pyrazol e-4-carboxylate (6)

The compound **6** was synthesized by the procedure as described above and obtained as a white solid: yield 61 %; mp: 190 $^{\circ}$ C; ¹H NMR (400

MHz, CDCl₃) δ 7.90 (d, *J* = 5.8 Hz, 1H), 7.72 – 7.66 (m, 1H), 7.63 – 7.56 (m, 2H), 7.55 – 7.48 (m, 2H), 7.32 (td, *J* = 7.4, 2.9 Hz, 2H), 7.24 – 7.19 (m, 1H), 3.92 (q, *J* = 7.1 Hz, 2H), 2.34 (s, 3H), 1.01 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 163.18, 149.65, 145.16, 144.00, 134.93, 134.03, 132.19, 131.31, 130.11, 129.61, 128.28, 126.41, 123.33, 122.50, 119.59, 110.86, 109.79, 77.35, 77.04, 76.72, 59.60, 13.94, 11.75. HRMS (ESI-ORBITRAP) m/z [M + H]⁺ calculated for C₂₀H₁₉N₄O₂ 347.3900, found 347.1508.

2.6 Synthetic procedure for compound (7)²**:**



An oven dried 25 ml round-bottom flask was taken compound **7a** (1.0 equiv, 1.20 mmol), NEt₃ (4.0 equiv, 4.81 mmol), and MsCl (3.0 equiv, 3.61 mmol) in dry DCM were added under nitrogen atmosphere, and the reaction was stirred to 0 °C at room temperature for 4 hours. Upon the completion of the reaction (confirm by TLC), the solvent was removed under reduced pressure, and the residue was dissolved in ethyl acetate. The organic layer was washed with water, dried over anhydrous Na₂SO₄, and removed under the reduced pressure. The crude was purified with silica gel column chromatography to afford the target compound **7b**.

The compound **7b** was again treated with KI (3.0 equiv, 4.79 mmol) in acetone under reflux condition for 4 hours. Upon the completion of the compound **7b** (confirm by TLC), the solvent was removed under reduced pressure, and the residue was dissolved in ethyl acetate. The organic layer was washed with water, dried over anhydrous Na_2SO_4 , and removed under the reduced pressure.

The crude was again treated with benzimidazole **1a** (1.1 equiv, 1.75 mmol), and NaH (1.1 equiv, 1.75 mmol) in DMF at room temperature. Upon the completion of the reaction (confirm by TLC), the solvent was removed under reduced pressure, and the residue was dissolved in ethyl acetate. The organic layer was washed with water, dried over anhydrous Na₂SO₄, and removed under the reduced pressure. The crude was further treated with hydrazine hydrate (1.5 equiv, 2.41 mmol) in methanol solvent under reflux condition for 6 hours. Upon the completion of the reaction (confirm by TLC), the solvent was removed under reduced pressure, and the residue was dissolved in ethyl acetate. The organic layer was washed with water, dried over anhydrous Na₂SO₄, and removed under the reduced pressure was removed under reduced pressure, and the residue was dissolved in ethyl acetate. The organic layer was washed with water, dried over anhydrous Na₂SO₄, and removed under the reduced pressure. The crude was purified with silica gel column chromatography to afford the target compound **7**.



2-((1H-benzo[d]imidazol-1-yl)methyl)-1H-benzo[d]imidazole (7)

The compound **7** was synthesized by the procedure as described above and obtained as a white solid: yield 65%; mp: > 260 °C; ¹H NMR (400 MHz,

DMSO d_6) δ 12.76 (s, 1H), 8.40 (s, 1H), 7.65 (dd, J = 5.7, 3.3 Hz, 1H), 7.56 – 7.51 (m, 2H), 7.24 – 7.09 (m, 5H), 5.74 (s, 2H). ¹³C NMR (101 MHz, DMSO d_6) δ 150.11, 144.96, 143.90, 134.34, 122.96, 122.15, 119.92, 111.03, 42.84, 40.62, 40.41, 40.20, 39.99, 39.78, 39.57, 39.36. HRMS (ASAP/Q-TOF) m/z [M + H]⁺ calculated for C₁₅H₁₃N₄ 249.1062, found 249.1103.

3. Experimental procedure for control experiments

3.1 Reaction to test the radical formation:



An oven dried schlenk tube was taken with compound **4a** (1.0 equiv, 0.38 mmol), TEMPO (1.0 equiv, 0.38 mmol), and $Cu(OAc)_2$ (20 mol%) in DMF solvent. The schlenk tube was flush with argon gas and maintain the inert argon atmosphere. The reaction mixture was stirred at 70 °C for 12 hours. Upon the completion of the reaction (confirm by TLC), the solvent was removed under reduced pressure, and the residue was dissolved in ethyl acetate. The organic layer was washed with water, dried over anhydrous Na₂SO₄, and removed under the reduced pressure. The crude was purified with silica gel column chromatography to afford the target compound **8a** with 82% yield.

3.2 Reaction to test the Cu-nanoparticle formation:



An oven dried schlenk tube was taken with compound **4a** (1.0 equiv, 0.38 mmol), Hg (10 mol%), and $Cu(OAc)_2$ (20 mol%) in DMF solvent. The schlenk tube was flush with argon gas and maintain the inert argon atmosphere. The reaction mixture was stirred at 70 °C for 12 hours. Upon the completion of the reaction (confirm by TLC), the solvent was removed under reduced pressure, and the residue was dissolved in ethyl acetate. The organic layer was washed with water, dried over anhydrous Na₂SO₄, and removed under the reduced pressure. The crude was purified with silica gel column chromatography to afford the target compound **8a** with 80% yield.

3.3 Intermolecular C-N coupling with Phenyl boronic acid:



An oven dried schlenk tube was taken with compound **4a** (1.0 equiv, 0.38 mmol), phenyl boronic acid **12** (1.0 equiv, 0.38 mmol), and Cu(OAc)₂ (1.0 equiv, 0.38 mmol) in DMF solvent. The schlenk tube was flush with argon gas and maintain the inert argon atmosphere. The reaction mixture was stirred at 70 °C for 12 hours. Upon the completion of the reaction (confirm by TLC), the solvent was removed under reduced pressure, and the residue was dissolved in ethyl acetate. The organic layer was washed with water, dried over anhydrous Na₂SO₄, and removed under the reduced pressure. The crude was purified with silica gel column chromatography to afford the white solid with 69% yield (mp: 192 °C) of target compound **13**.

¹H NMR (400 MHz, CDCl₃) δ 8.17 (dd, J = 7.8, 1.3 Hz, 1H), 7.96 (s, 1H), 7.89 (d, J = 8.0 Hz, 1H), 7.67 – 7.60 (m, 2H), 7.57 – 7.47 (dtd, J = 15.7, 7.8, 1.3 Hz, 4H), 7.40 (t, J = 7.9 Hz, 2H), 7.35 – 7.29 (m, 1H), 7.23 (dd, J = 14.2, 7.0 Hz, 3H), 5.56 (d, J = 2.5 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 148.92, 143.48, 143.25, 139.77, 135.03, 133.11, 131.36, 130.21, 129.57, 129.39, 129.08, 128.40, 127.79, 126.58, 123.57, 122.48, 120.20, 118.97, 110.63, 106.59, 77.35, 77.03, 76.71. HRMS (ESI-ORBITRAP) m/z [M + H]⁺ calculated for C₂₂H₁₇N₄ 337.1375, found 337.1439.

3.4 Synthetic procedure for 1-(2-(1H-pyrazol-3-yl)phenyl)-1H-indole (14):



An oven dried 25 ml round-bottom flask was taken indole **14a** (1.0 equiv, 2.56 mmol), 2-iodoacetophenone **14b** (0.8 equiv, 2.12 mmol) CuI (0.25 equiv, 0.64 mmol), and K_2CO_3 (2.5 equiv, 6.40 mmol) in DMF (3.0 ml) were added, and the reaction was stirred at 90-100 °C for 24 hours. Upon the completion of the reaction (confirm by TLC), the solvent was removed under reduced pressure, and the residue was dissolved in ethyl acetate. The organic layer was washed with water, dried over anhydrous Na₂SO₄, and removed under the reduced pressure. The crude was purified with silica gel column chromatography to afford the target compound **14c³**.

An oven dried 25 ml round-bottom flask was taken compound 14c (1.0 equiv, 1.06 mmol), and DMF-

DMA (2.5 equiv, 2.65 mmol) in DMF solvent were added, and the reaction was stirred to reflux overnight. Upon the completion of the reaction (confirm by TLC), the solvent was removed under reduced pressure, and the residue was dissolved in ethyl acetate. The organic layer was washed with water, dried over anhydrous Na₂SO₄, and removed under the reduced pressure. The crude was again treated with hydrazine hydrate (2 equiv, 2.06 mmol) in ethanol under reflux condition for 4 hours. Upon the completion of the reaction (confirm by TLC), the solvent was removed under reduced pressure, and the residue was dissolved in ethyl acetate. The organic layer was washed with water, dried over anhydrous Na₂SO₄, and removed under the reduced pressure. The crude was purified over anhydrous Na₂SO₄, and removed under the reduced pressure. The crude was purified with silica gel column chromatography to afford the colorless sticky liquid with 68% yield of target compound **14**.

¹H NMR (400 MHz, CDCl₃) δ 8.01 – 7.95 (m, 1H), 7.74 (t, *J* = 11.1 Hz, 1H), 7.71 – 7.65 (m, 1H), 7.52 (ddd, *J* = 10.6, 8.0, 1.5 Hz, 2H), 7.48 – 7.38 (m, 2H), 7.17 – 7.11 (m, 2H), 7.10 (t, *J* = 3.2 Hz, 1H), 7.07 (t, *J* = 3.9 Hz, 1H), 6.66 (d, *J* = 3.1 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 136.91, 136.31, 130.28, 129.52, 129.15, 128.95, 128.84, 128.69, 128.66, 128.39, 128.08, 125.75, 122.40, 120.91, 120.24, 110.49, 103.32, 77.35, 77.04, 76.72. HRMS (ESI-ORBITRAP) m/z [M + H]⁺ calculated for C₁₇H₁₄N₃ 260.1109, found 260.1180.

3.5 Reaction to test the role of benzimidazole nitrogen:



An oven dried schlenk tube was taken with compound 14 (1.0 equiv, 0.5 mmol), and $Cu(OAc)_2$ (20 mol%) in DMF solvent. The schlenk tube was flush with argon gas and maintain the inert argon atmosphere. The reaction mixture was stirred at 70 °C for 12 hours even then no cyclization product 15 was form.

3.6 Synthetic procedure for 1-(2-(1H-pyrazol-3-yl)phenyl)-2-phenyl-1Hbenzo [d]imid azole (16):



An oven dried 25 ml round-bottom flask was taken compound 2b (1.0 equiv, 1.56 mmol), and DMF-

DMA (2.5 equiv, 3.90 mmol) in DMF solvent were added, and the reaction was stirred to reflux overnight. Upon the completion of the reaction (confirm by TLC), the solvent was removed under reduced pressure, and the residue was dissolved in ethyl acetate. The organic layer was washed with water, dried over anhydrous Na₂SO₄, and removed under the reduced pressure. The crude was again treated with hydrazine hydrate (2.0 equiv, 3.12 mmol) in ethanol under reflux condition for 4 hours. Upon the completion of the reaction (confirm by TLC), the solvent was removed under reduced pressure, and the residue was dissolved in ethyl acetate. The organic layer was washed with water, dried over anhydrous Na₂SO₄, and removed under the reduced pressure. The crude was purified with silica gel column chromatography to afford the target compound **16a**.

An oven dried 25 ml round-bottom flask was taken compound **16a** (1.0 equiv, 1.23 mmol), compound **16b** (1.0 equiv, 1.23 mmol), and K_2CO_3 (2.0 equiv, 2.46 mmol) in CH₃CN (5.0 ml) were added, and the reaction was stirred at reflux for 19 hours. Upon the completion of the reaction (confirm by TLC), the solvent was removed under reduced pressure, and the residue was dissolved in ethyl acetate. The organic layer was washed with water, dried over anhydrous Na₂SO₄, and removed under the reduced pressure. The crude was purified with silica gel column chromatography to afford the pale yellow sticky liquid with yield 45% of target compound **16**.

H NMR (400 MHz, CDCl₃) δ 8.06 (dt, J = 4.4, 2.5 Hz, 3H), 7.82 (td, J = 7.7, 1.7 Hz, 1H), 7.67 – 7.64 (m, 3H), 7.48 (t, J = 5.7 Hz, 4H), 7.28 (d, J = 3.2 Hz, 1H), 7.22 (dt, J = 6.5, 3.3 Hz, 1H), 7.20 – 7.14 (m, 1H), 6.74 (dd, J = 5.0, 2.9 Hz, 1H).

3.7. Intramolecular C-N coupling with 2-phenyl benzimidazole:



An oven dried schlenk tube was taken with compound **16** (1.0 equiv, 0.5 mmol), and $Cu(OAc)_2$ (20 mol%) in DMF solvent. The schlenk tube was flush with argon gas and maintain the inert argon atmosphere. The reaction mixture was stirred at 70 ^{0}C for 12 hours even then no cyclized product form.

3.8 Reaction in hydrogen atmosphere:



An oven dried schlenk tube was taken with compound **4a** (1.0 equiv, 0.5 mmol), and Cu(OAc)₂ (20 mol%) in DMF solvent. The schlenk tube was flush with hydrogen gas and maintain the hydrogen atmosphere. The reaction mixture was stirred at 70 °C. After 12 hours solvent was removed under reduced pressure, and the residue was dissolved in ethyl acetate. The organic layer was washed with water, dried over anhydrous Na₂SO₄, and removed under the reduced pressure. The crude was purified with silica gel column chromatography to afford the target compound **8a** with 55% yield.

3.9 Headspace GC analysis:



An oven dried schlenk tube was filled with compound (**4a**) (5.0 mmol), and $Cu(OAc)_2$ (20 mol%) in dry DMF solvent. The schlenk tube was taken under vacuum to make the reaction moisture free atmosphere. The reaction mixture was stirred at 70 °C for 5 hours. After 5 hours, the gas was taken out with the help of gas trap syringe and injected to GC.



Figure S1. Hydrogen gas analysis by GC



Figure S2. Reaction Headspace GC analysis

4. Gram Scale and Synthetic Versatility4.1 Gram Scale procedure for Synthesis of compound (8a):



An oven dried RB was filled with compound **4a** (3.84 mmol) (1.0 gm) and Cu(OAc)₂ (20 mol%) in dry DMF solvent. The RB was flush with argon gas and maintain the inert atmosphere. The reaction mixture was stirred at 70 °C for 14 hours until the substrate was completely consumed (reaction monitor by TLC). After full conversion of starting material cool the reaction mixture to room temperature. The reaction mixture allows to rotary evaporator to evaporate solvent and extracted with ethyl acetate. The organic layer was washed with water and brine solution. The combined organic phase was dried over Na₂SO₄, filtered, and concentrated under reduced pressure then the crude product was purified by column chromatography over silica gel using a mixture of hexane/ ethyl acetate (4:1) as the eluent to afford cyclized product **8a** with 82% (813mg) yield.

4.2 Synthetic Versatility of compound (8a):

4.2.1 Synthetic procedure for 3-Chlorobenzo[4,5]imidazo[1,2-a]pyrazolo [1, 5-c] quinazoline (17):



An oven dried 25 ml round-bottom flask was taken compound **8a** (1.0 equiv, 0.8 mmol), and Ca(ClO)₂ (1.0 equiv, 0.8 mmol), in methanol: water (1:1) (2.0 ml) were added, and the reaction was stirred at room temperature for 10 hours. Upon the completion of the reaction (confirm by TLC), the solvent was removed under reduced pressure, and the residue was dissolved in ethyl acetate. The organic layer was washed with water, dried over anhydrous Na₂SO₄, and removed under the reduced pressure. The crude was purified with silica gel column chromatography to afford the white solid with 68% yield (mp: 200 °C) of target compound **17**.

¹H NMR (400 MHz, CDCl₃) δ 8.77 (dd, *J* = 8.0, 1.3 Hz, 1H), 8.39 (d, *J* = 8.4 Hz, 1H), 8.18 – 8.13 (m, 1H), 8.07 (s, 1H), 7.96 (dd, *J* = 7.2, 1.6 Hz, 1H), 7.78 – 7.71 (m, 1H), 7.57 – 7.52 (m, 1H), 7.46 (ddd, *J* = 15.7, 7.6, 1.3 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 143.66, 142.48, 141.29, 132.06, 131.08, 130.87, 130.63, 125.29, 124.95, 124.73, 123.49, 120.85, 115.15, 114.81, 113.04, 107.49, 77.34, 77.03, 76.71. HRMS (ASAP/Q-TOF) m/z [M + H]⁺ calculated for C₁₆H₁₀N₄Cl 293.7260, found 293.0544.

4.2.2 Synthetic procedure for 3-Bromobenzo[4,5]imidazo[1,2-a]pyrazolo [1,5-c] quinazoline (18):



An oven dried 25 ml round-bottom flask was taken compound **8a** (1.0 equiv, 0.8 mmol), and NBS (1.0 equiv, 0.8 mmol), in CH₃CN (2.0 ml) were added, and the reaction was stirred at room temperature for 12 hours. Upon the completion of the reaction (confirm by TLC), the solvent was removed under reduced pressure, and the residue was dissolved in ethyl acetate. The organic layer was washed with water, dried over anhydrous Na_2SO_4 , and removed under the reduced pressure. The crude was purified with silica gel column chromatography to afford the white solid with 64% yield (mp: 205 °C) of target compound **18**.

¹H NMR (400 MHz, CDCl₃) δ 8.77 (dd, *J* = 8.0, 1.3 Hz, 1H), 8.39 (d, *J* = 8.4 Hz, 1H), 8.18 – 8.13 (m, 1H), 8.07 (s, 1H), 7.96 (dd, *J* = 7.2, 1.6 Hz, 1H), 7.78 – 7.71 (m, 1H), 7.57 – 7.52 (m, 1H), 7.46 (ddd, *J* = 15.7, 7.6, 1.3 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 143.66, 142.48, 141.29, 132.06, 131.08, 130.87, 130.63, 125.29, 124.95, 124.73, 123.49, 120.85, 115.15, 114.81, 113.04, 107.49, 77.34, 77.03, 76.71. HRMS (ASAP/Q-TOF) m/z [M+H]⁺ calculated for C₁₆H₁₀N₄Br 337.0011, found 337.9977.

4.2.3 Synthetic procedure for 3-Iodobenzo[4,5]imidazo[1,2-a]pyrazolo[1,5c] quinazoline (19)⁴:



An oven dried 25 ml round-bottom flask was taken compound **8a** (1.0 equiv, 0.8 mmol), CAN (1.0 equiv, 0.8 mmol), and I₂ (1.0 equiv, 0.8 mmol), in CH₃CN (2.0 ml) were added, and the reaction was stirred at room temperature for 8 hours. Upon the completion of the reaction (confirm by TLC), the solvent was removed under reduced pressure, and the residue was dissolved in ethyl acetate. The organic layer was washed with water, dried over anhydrous Na₂SO₄, and removed under the reduced pressure. The crude was purified with silica gel column chromatography to afford the white solid with 72% yield (mp: >260 °C) of target compound **19**.

¹H NMR (400 MHz, CDCl₃) δ 9.19 (dd, *J* = 8.1, 1.3 Hz, 1H), 8.45 (d, *J* = 8.3 Hz, 1H), 8.24 – 8.17 (m, 1H), 8.15 (s, 1H), 8.02 – 7.95 (m, 1H), 7.85 – 7.76 (m, 1H), 7.62 – 7.55 (m, 1H), 7.55 – 7.44 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 150.84, 144.92, 130.94, 129.58, 124.92, 124.92, 124.86, 124.81, 123.95, 123.49, 123.49, 122.08, 120.89, 116.59, 115.33, 113.13, 77.34, 77.02, 76.70. HRMS (ESI-ORBITRAP) m/z [M + H]⁺ calculated for C₁₆H₉N₄I 385.9872, found 384.9937.

4.2.4 Synthetic procedure for 3-(3-(6-methoxy-9H-purin-9-yl) prop-1-yn-1yl) benzo [4,5] imidazo[1,2-a] pyrazolo[1,5-c] quinazoline (19a):



An oven dried 25 ml round-bottom flask was taken compound **19** (1.0 equiv, 0.8 mmol), Pd(PPh₃)₂Cl₂ (10 mol%), CuI (10 mol%), phenyl acetylene (1.0 equiv, xmmol) and NEt₃ (2.5 equiv, 2.0 mmol), in DMF (2.0 ml) were added, and the reaction was stirred at 60 $^{\circ}$ C for 10 hours. Upon the completion of the reaction (confirm by TLC), the solvent was removed under reduced pressure, and the residue was dissolved in ethyl acetate. The organic layer was washed with water, dried over anhydrous Na₂SO₄, and removed under the reduced pressure. The crude was purified with silica gel column chromatography to afford the white solid with 48% yield (mp: 197 $^{\circ}$ C) of target compound **19a**.

¹H NMR (400 MHz, CDCl₃) δ 8.77 (dd, *J* = 8.0, 1.3 Hz, 1H), 8.66 (s, 1H), 8.43 (d, *J* = 8.3 Hz, 1H), 8.26 (s, 1H), 8.20 (d, *J* = 6.7 Hz, 2H), 8.03 – 7.96 (m, 1H), 7.82 – 7.74 (m, 1H), 7.54 – 7.45 (m, 3H), 5.45 (s, 2H), 4.23 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 161.31, 152.55, 152.24, 151.69, 147.32, 142.45, 141.95, 141.37, 141.21, 137.03, 132.31, 131.33, 130.85, 125.41, 124.89, 123.66, 120.95, 115.23, 114.99, 113.09, 98.22, 96.13, 87.41, 77.34, 77.02, 76.70, 54.41, 29.70. HRMS (ESI-ORBITRAP) m/z [M + H]⁺ calculated for C₂₅H₁₆N₈O 445.1447, found 445.2563.

4.2.5 Synthetic procedure for 3-((4-Pentylphenyl) ethynyl) benzo [4,5] imidazo [1,2-a] pyrazolo [1, 5-c] quinazoline (19b):



An oven dried 25 ml round-bottom flask was taken compound **19** (1.0 equiv, 0.8 mmol), Pd(PPh₃)₂Cl₂ (10 mol%), CuI (10 mol%), phenyl acetylene (1.0 equiv, 0.8 mmol) and NEt₃ (2.5 equiv, 2.0 mmol), in DMF (2.0 ml) were added, and the reaction was stirred at 60 $^{\circ}$ C for 10 hours. Upon the completion of the reaction (confirm by TLC), the solvent was removed under reduced pressure, and the residue was dissolved in ethyl acetate. The organic layer was washed with water, dried over anhydrous Na₂SO₄, and removed under the reduced pressure. The crude was purified with silica gel column chromatography to afford the white solid 61% yield (mp: 215 °C) of target compound **19b**.

¹H NMR (400 MHz, CDCl₃) δ 9.04 (dd, J = 8.0, 1.4 Hz, 1H), 8.45 (d, J = 8.4 Hz, 1H), 8.26 (s, 1H), 8.24 – 8.19 (m, 1H), 8.03 – 7.97 (m, 1H), 7.82 – 7.75 (m, 1H), 7.57 (dd, J = 10.8, 8.2 Hz, 3H), 7.54 – 7.45 (m, 2H), 7.24 (s, 2H), 2.72 – 2.63 (m, 2H), 1.67 (dd, J = 15.0, 7.6 Hz, 2H), 1.36 (dd, J = 7.2, 3.8 Hz, 4H), 0.92 (t, J = 6.9 Hz, 3H).¹³C NMR (101 MHz, CDCl₃) δ 147.15, 144.14, 142.59, 141.53, 135.94, 132.25, 131.44, 130.95, 130.83, 128.73, 125.58, 125.43, 124.73, 123.45, 120.84, 119.99, 115.65,

115.11, 113.06, 100.41, 95.68, 79.59, 77.34, 77.02, 76.70, 35.95, 31.46, 30.98, 22.54, 14.03. HRMS (ESI-ORBITRAP) m/z $[M + H]^+$ calculated for C₂₉H₂₄N₄ 429.5390, found 429.2064.

4.2.6 Synthetic procedure for (E)-3-(4-Methylstyryl) benzo [4,5] imidazo[1,2-a] pyrazolo[1,5-c] quinazoline (19c):



An oven dried 25 ml round-bottom flask was taken compound **19** (1.0 equiv, 0.8 mmol), Pd(PPh₃)₂Cl₂ (10 mol%), NEt₃ (2.0 equiv, 1.6 mmol), and phenyl styrene (1.0 equiv, 0.8 mmol) in DMF (2.0 ml) were added, and the reaction was stirred at 120 0 C for 12 hours. Upon the completion of the reaction (confirm by TLC), the solvent was removed under reduced pressure, and the residue was dissolved in ethyl acetate. The organic layer was washed with water, dried over anhydrous Na₂SO₄, and removed under the reduced pressure. The crude was purified with silica gel column chromatography to afford the white solid with 58% yield (mp: 210 °C) of target compound **19c.**

¹H NMR (400 MHz, CDCl₃) δ 8.42 (d, *J* = 8.3 Hz, 1H), 8.36 – 8.29 (m, 2H), 8.18 (d, *J* = 7.8 Hz, 1H), 7.99 – 7.95 (m, 1H), 7.75 – 7.68 (m, 1H), 7.53 (dd, *J* = 9.0, 5.6 Hz, 1H), 7.50 – 7.40 (m, 5H), 7.24 (d, *J* = 8.0 Hz, 2H), 7.13 (d, *J* = 16.1 Hz, 1H), 2.40 (d, *J* = 5.1 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 143.24, 142.08, 138.17, 136.90, 132.28, 129.85, 129.59, 128.40, 126.45, 125.44, 125.34, 124.54, 123.14, 121.07, 120.66, 119.57, 118.09, 118.01, 116.54, 116.38, 115.44, 112.98, 77.34, 77.02, 76.70, 21.34. HRMS (ASAP/Q-TOF) m/z [M + H]⁺ calculated for C₂₅H₁₉N₄ 375.4470, found 375.1531.

4.2.7 Synthetic procedure for 3-phenylbenzo [4,5] imidazo[1,2-a] pyrazolo[1,5-c] quinazoline (19d):



An oven dried 25 ml round-bottom flask was taken compound **19** (1.0 equiv, 0.8 mmol), Pd(PPh₃)₄ (0.05 mol%), Cs₂CO₃ (2.0 equiv, 1.6 mmol), and phenyl boronic acid (1.2 equiv, 0.96 mmol) in dry THF (2.0 ml) were added, and the reaction was stirred at 60 °C for 8 hours. Upon the completion of the reaction (confirm by TLC), the solvent was removed under reduced pressure, and the residue was dissolved in ethyl acetate. The organic layer was washed with water, dried over anhydrous Na₂SO₄, and

removed under the reduced pressure. The crude was purified with silica gel column chromatography to afford the white solid with 55% yield (mp: 245°C) of target compound **19d.**

¹H NMR (400 MHz, CDCl₃) δ 8.41 (d, *J* = 8.4 Hz, 1H), 8.19 (d, *J* = 7.6 Hz, 1H), 8.08 (s, 1H), 8.03 (dd, *J* = 8.1, 1.3 Hz, 1H), 7.99 (dd, *J* = 7.9, 1.0 Hz, 1H), 7.69 – 7.64 (m, 1H), 7.60 – 7.54 (m, 4H), 7.49 (dddd, *J* = 14.1, 12.4, 5.3, 3.7 Hz, 4H). ¹³C NMR (101 MHz, CDCl₃) δ 145.48, 142.80, 142.05, 132.24, 132.10, 130.98, 130.10, 129.75, 129.10, 128.30, 124.91, 124.89, 124.54, 123.17, 120.71, 120.21, 115.91, 115.36, 113.01, 77.34, 77.03, 76.71. HRMS (ESI-ORBITRAP) m/z [M + H]⁺ calculated for C₂₂H₁₄N₄ 335.1218, found 335.1283.

4.2.8 Synthetic procedure for 3-(phenylethynyl) indolo[1,2-a] pyrazolo [1,5c] quinazoline (19e):



An oven dried 25 ml round-bottom flask was taken compound **19** (1.0 equiv, 0.8 mmol), Pd(PPh₃)₂Cl₂ (10 mol%), CuI (10 mol%), phenyl acetylene (1.0 equiv, 0.8 mmol) and NEt₃ (2.5 equiv, 2.0 mmol), in DMF (2.0 ml) were added, and the reaction was stirred at 60 $^{\circ}$ C for 10 hours. Upon the completion of the reaction (confirm by TLC), the solvent was removed under reduced pressure, and the residue was dissolved in ethyl acetate. The organic layer was washed with water, dried over anhydrous Na₂SO₄, and removed under the reduced pressure. The crude was purified with silica gel column chromatography to afford the white solid with 68% yield (mp: 250 $^{\circ}$ C) of target compound **19e**.

¹H NMR (400 MHz, CDCl₃) δ 9.02 (dd, *J* = 8.0, 1.3 Hz, 1H), 8.44 (d, *J* = 8.4 Hz, 1H), 8.27 (s, 1H), 8.22 - 8.19 (m, 1H), 8.01 - 7.97 (m, 1H), 7.80 - 7.75 (m, 1H), 7.64 (dd, *J* = 7.4, 2.2 Hz, 2H), 7.57 (t, *J* = 7.4 Hz, 1H), 7.50 (td, *J* = 7.2, 1.4 Hz, 2H), 7.46 - 7.41 (m, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 147.13, 142.57, 141.45, 136.04, 132.26, 131.49, 130.92, 130.87, 128.78, 128.60, 125.53, 125.40, 124.73, 123.46, 122.88, 120.85, 115.54, 115.10, 113.04, 100.15, 95.41, 80.30, 77.33, 77.01, 76.70. HRMS (ESI-ORBITRAP) m/z [M + H]⁺ calculated for C₂₄H₁₄N₄ 359.1218, found 359.1286.

5. References

- 1. S. Sahoo, S. Pal, J. Org. Chem., 2021, 86, 4081-4097.
- K. L. Yu, R. L. Civiello, K. D. Combrink, H. B. Gulgeze, N. Sin, X. Wang, N. Meanwell, B. L. Venables, Y. Zhang, B. C. Pearce, Z. Yin, J. W. Thuring, United States Patent Application Publication US 2002/0099208 A1, 2002, 09, 994,012.
- 3. Y. Mu, Y. Yuan, Y. Wang, M. Xu, Y. Feng, Y. Zhao, Y. Li, Org. Biomol. Chem., 2020, 18, 6916.
- 4. M. I. R. Franco, I. Dorronsoro, A. I. H. Higueras, G. Antequera, *Tetrahedron Lett.*, 2001, **42**, 863–865.

6. Copy of ¹H NMR and ¹³C NMR spectra 6.1 ¹H NMR and ¹³C NMR spectra of compound 8a:





6.2 ¹H NMR and ¹³C NMR spectra of compound 8b:







6.4 ¹H NMR and ¹³C NMR spectra of compound 9a:





6.5 ¹H NMR and ¹³C NMR spectra of compound 9b:



6.6 ¹H NMR and ¹³C NMR spectra of compound 9c:



6.7 ¹H NMR and ¹³C NMR spectra of compound 9d-e:









6.10 ¹H NMR and ¹³C NMR spectra of compound 10aa:



6.11 ¹H NMR and ¹³C NMR spectra of compound 10ab:



6.12 ¹H NMR and ¹³C NMR spectra of compound 10ac:



6.13 ¹H NMR and ¹³C NMR spectra of compound 3aa:















6.17 ¹H NMR and ¹³C NMR spectra of compound 3af-ag:





















6.21 ¹H NMR and ¹³C NMR spectra of compound 5d-e:











6.23 ¹H NMR and ¹³C NMR spectra of compound 3ba:







6.25 ¹H NMR and ¹³C NMR spectra of compound 3bc:





¹³C NMR (DMSO-d₆)



S52 | Page







6.29 ¹H NMR and ¹³C NMR spectra of compound 6:





6.31 ¹H NMR and ¹³C NMR spectra of compound 13:







6.32 ¹H NMR and ¹³C NMR spectra of compound 14:





6.33 ¹H NMR and ¹³C NMR spectra of compound 16:





6.34 ¹H NMR and ¹³C NMR spectra of compound 17:





6.35 ¹H NMR and ¹³C NMR spectra of compound 18:



6.36 ¹H NMR and ¹³C NMR spectra of compound 19:





6.37 ¹H NMR and ¹³C NMR spectra of compound 19a:





6.38 ¹H NMR and ¹³C NMR spectra of compound 19b:

6.39 ¹H NMR and ¹³C NMR spectra of compound 19c:



6.40 ¹H NMR and ¹³C NMR spectra of compound 19d:



6.41 ¹H NMR and ¹³C NMR spectra of compound 19e:



9.03 9.03 9.04 9.05





7. Photophysical Studies

UV-Vis and Emission spectres:







S**68** | Page









Figure S5 Absorption and fluorescence emission spectra in CHCl₃ at 5×10^{-6} mol/L.